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ABSTRACT 
Direct oral anti-coagulant (DOAC) has been used in patients with 
non-valvular AF, and renal function is recommended to be evaluated using 
the CCr (Cockcroft-Gault) as reduction criteria of DOAC. In contrast, 
estimated glomerular filtration rate (eGFR) is usually used as an index of 
renal function in the daily practice. We determined age- and gender-specific 
prevalence rate of AF, and whether CCr or eGFR was associated with the 
prevalence of AF. Data of 108,951 subjects were collected from the periodic 
health examination. Risk factors of AF were evaluated by the medical history, 
physical examination and blood sampling, and AF was diagnosed by the 
electrocardiography.  
The prevalence rate of AF was 0.92% (998/108,951) and there was four times 
higher in men than in women and increased with age. Cardiac disease (odds 
ratio: OR = 27.07, confidential interval: CI 23.39-31.37, p = 0.0001), female 
(OR = 3.65, CI 3.11-4.30), age > 65 years old (OR = 2.52, CI 2.14-2.96), 
hyperlipidemia (OR = 2.51, CI 1.97-3.20), BMI >25 kg/m2 (OR=1.37, CI 
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1.19-1.58), hypertension (OR = 1.14, CI 1.11-1.16) were independently high 
risks of prevalence of AF in the multivariate logistic regression analysis, 
respectively. The odds ratio of the risk of having AF was significantly higher 
in eGFR≦59 (OR=2.10, CI: 1.21-3.86) than in eGFR≧90 but not CCr after 
adjustment of age, gender, diabetes mellitus and smoking. However, this 
significance disappeared after additional adjustment of hypertension. 
Cardiac disease, gender, aging, hyperlipidemia, obesity, hypertension and 
renal dysfunction were strong risk factors for prevalence of AF. The 
evaluation of renal dysfunction as a morbidity risk of atrial fibrillation was 
suggested that eGFR should be used.  
 
 
Key words: atrial fibrillation, estimated glomerular filtration ratio, 
creatinine clearance, hypertension,  
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INTRODUCTION 
 Atrial fibrillation (AF) is the most common cardiac arrhythmia especially 
in old generation.1 AF was frequently observed as comorbid disease in 
patients with hypertension, which was induced by several risk factors such 
as aging, left ventricular hypertrophy and left atrial enlargement.2 
Alternatively, aging, hypertension and diabetes mellitus were also associated 
with chronic kidney disease (CKD), which had the onset risk of AF3 and 
would influence large impact of its prognosis.4,5  
 Recently, direct oral anti-coagulants (DOAC) have been used in the 
practical medicine, and the impaired renal function may lead to expression 
of bleeding complications in patients with administration of DOAC.6,7  The 
index of renal function was creatinine clearance (CCR); the Cockcroft-Gault 
equation was specified in United State Food and Drug administration 
approved prescribing information of DOAC.8 Although studies were limited 
to evaluate the relationship between CCr and adverse clinical outcomes in 
AF patients with anticoagulant,9–11 the recent sub-analysis of Fushimi AF 
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registry demonstrated that the group of CCr<30 ml/min had significant 
higher stroke, systemic embolization and major bleeding rates than other 
groups (30<CCr<50 ml/min, 50 ml/min<CC) in the entire cohort and the 
cohort without oral anticoagulant.12 In contrast, the early detection of kidney 
disease, a simple index; the estimated GFR (eGFR), which is calculated from 
creatinine and age have been used, and the lower levels of eGFR stages 
independently associated with the risks of death, cardiovascular events, and 
hospitalization.13 However, to our knowledge, there was no study comparing 
CCr and eGFR for the onset risk of AF. Moreover, there was few current data 
that examined the prevalence of AF and the risk factor of AF in the large 
cohort. Therefore, we determined the age and gender-specific prevalence rate 
of AF, and revealed the risk factor of AF, and also compared which was better 
index of eGFR and CCr as evaluating renal function associated with the 
onset risk of AF. 
 
METHODS 
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 Subjects had periodic health examination of community resident and 
employees of companies and governments from April 2013 to March 2014 in 
Tochigi Prefecture, in Japan. The informed consents were written in all 
subjects. The study design was approval in the ethics community of the 
Tochigi Public Health Service Association, and data were collected from the 
database of this institution. The ethic committee of Dokkyo Medical 
University according to the Declaration of Helsinki also approved study 
protocol. 
 Symptom and medical history including hypertension, diabetes mellitus, 
dyslipidemia, cardiac disease and smoking habit were collected by the 
questionnaire. Each item was classified in 4 categories as follow: the 
currently treatment, only follow-up, completion of treatment and without 
treatment. The medical history was positive if there was more than one item. 
The smoking habit was defined as positive history of smoking within the 
past 5 years. 
 Physical examination including blood pressure, electrocardiography, blood 
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sampling (serum creatinine, fasting glucose, hemoglobin A1c, 
LDL-cholesterol, HDL-cholesterol, triglyceride, uric acid and hemoglobin), 
body weight and height was underwent. Blood pressure was measured in the 
sitting and resting position after few minutes. Body mass index was 
calculated as weight by square of height. Hypertension was defined as 
currently treatment of antihypertensive drugs and/or systolic blood pressure
≧140 mmHg or diastolic blood pressure ≧ 90 mmHg on healthy check-up. 
Diabetes mellitus was defined as currently treatment of oral hypoglycemic 
drugs and/or insulin, glucagon-like peptide-1 agonist or fasting blood glucose
≧126 mg/dl or/and HbA1c≧6.5%. Dyslipidemia was defined as currently 
treatment of hypolipidemic drugs or serum LDL-cholesterol ≧140 mg/dl 
and/or HDL-cholesterol<40 mg/dl and/or triglyceride≧150 mg/dl.  
 eGFR was calculated by the 3-variable Japanese equation: eGFR 
(ml/min/1.73m2) = 194 × Age-0.287 × Serum creatinine-1.094 × 0.739 (if 
female).14 Renal function were categorized by the eGFR level as ≧90, 60-89, 
≦59.15 CCr was also calculated by Cockcroft-Gault equation: CCr (ml/min) =  
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((140-Age) × Body weight)/(72 × Serum creatinine) × 0.85 (if female).16 
Another renal function was categorized by the CCr level as ≧80, 50-79, 
<50).17-19 
 AF was diagnosed by the automatic computerized analysis that was 
performed with the ECG recorder FCP-7431 (Fukuda Denshi, Tokyo, Japan) 
at the time of health examination. Conventional diagnostic criteria AF, i.e., a 
glossary irregular ventricular rhythm of supraventricular origin, no visible P 
wave and irregular fluctuation of the baseline, were employed. Almost of all 
subjects with AF who diagnosed by automatic ECG system were followed by 
hospital to confirm its diagnosis.  
 
Statistical analysis 
 All continuous calculated data are expressed as the mean ± SD. Categorical 
data was presented proportion (%). Baseline characteristics differences 
between groups were analyzed by Student t test or analysis variance of 
continuous (ANOVA). The variables of AF risk were analyzed by 
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multivariate logistic regression analysis. Chi-square test was used for 
analyzing categorical variables with percentage (%). Odds ratios (ORs) with 
95% confidence intervals (CIs) were calculated in all of the regression 
analyses. Multivariate regression analysis was used to evaluate the 
association between eGFR, CCr and prevalence of AF. First, all associations 
were adjusted by age and gender, additionally by hypertension, diabetes 
mellitus, cardiac disease and smoking. The relationships between eGFR or 
CCr and age or body mass index (BMI) were assessed by Pearson's 
correlation coefficient (r). Statistical analysis was performed using JMP 10.0 
software (SAS Institute, Carry, NC, USA). Statistical significance was 
accepted at p < 0.05.  
 
RESULTS 
 Total 108,951 subjects were registered in this cross sectional study. The 
number of including men and women were 54,645 and 54,306 respectively, 
which were almost equal. The total prevalence rate of AF was 0.92% 
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(998/108,951) and there was four times higher in men than in women (1.46% 
vs. 0.37%, p<0.0001). The prevalence of AF in for each decade of advancing 
age of men and women were shown in Table 1. Although the prevalence of AF 
increased with aging, that were higher in men than in women in each age 
group. Of note, AF was rare <60 years old in men (95/32,407: 0.29%) or <70 
years old in women (62/44,609: 0.14%), respectively.  
 Baseline clinical characteristics in subjects with or without AF were shown 
in Supplementary table 1. Almost one-third of men and the half of women 
had palpitation or feeling irregular pulse in AF subjects. Hypertension, 
diabetes mellitus, dyslipidemia and cardiac disease were more frequently 
comorbid in subjects with AF than in those without AF in both genders, 
respectively (p<0.0001, respectively). Smokers were however, lesser in AF 
than non-AF subjects in men (p<0.0001) and women (p<0.05). Cardiac 
disease (odds ratio: OR = 27.07, confidential interval: CI 23.39-31.37, p = 
0.0001), female (OR = 3.65, CI 3.11-4.30), age > 65 years old (OR = 2.52, CI 
2.14-2.96, p = 0.0001), hyperlipidemia (OR = 2.51, CI 1.97-3.20, p = 0.0001), 
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BMI >25 kg/m2 (OR=1.37, CI 1.19-1.58, p = 0.0004), hypertension (OR = 1.14, 
CI 1.11-1.16, p = 0.001) were independently high risks of prevalence of AF in 
the multivariate logistic regression analysis, respectively as shown in Table 
2. Furthermore, the logistic regression analysis of the continuous variables 
revealed that systolic blood pressure (odds ratio: OR=1.07, CI 1.03-1.11, 
p<0.0001) at the time of health examination was only positively associated 
with prevalence of AF.  
 There was baseline clinical characteristics when the CKD were categorized 
by the eGFR level as ≧90, 60-89, <59 were shown in Table 3. Total 85,414 
subjects whose serum creatinine were available could be analyzed, and 
subjects with AF were 884 (1.04%). According to decreasing eGFR, the 
prevalence of atrial fibrillation as well as hypertension, dyslipidemia, 
cardiac disease, and systolic blood pressure increased, and it became elderly, 
body weights were however, almost similar as shown in Table 3.  
 If the odds ratio (OR) of the risk of having AF at the eGFR≧90 was 
calculated as 1, there was significantly high risks at eGFR 60-89 (OR=1.53, 
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CI: 1.14-2.12) and eGFR≦59 (OR=2.61, CI: 1.95-3.75) after adjustment of 
the age and gender. After additional adjustment of diabetes mellitus and 
smoking, there was still significantly high risk at eGFR≦59 (OR=2.10, CI: 
1.21-3.86) as shown in Table 4. However, this significance disappeared after 
additional adjustment of hypertension. Thus, the hypertension was one of 
the strong covariates of risk of having AF in subject with eGFR≦59.  
 In contrast, there was baseline clinical characteristics when the renal 
function were categorized by the CCr level as ≧80, 50-79, <50 were shown 
in Table 5. Total 84,931 subjects could be analyzed, and subjects with AF 
were 861 (1.01%). According to decreasing CCr, the prevalence of atrial 
fibrillation as well as hypertension, dyslipidemia, cardiac disease, and 
systolic blood pressure increased, and it became elderly. Of note, body 
weights were decreased with lowering CCr as shown in Table 5. 
 If the odds ratio (OR) of the risk of having AF at the CCr≧80 was calculated 
as 1, the odd ratios did not differ among three groups after adjustment of the 
age and gender (CCr 50-79: OR=0.97, CI: 0.82-1.15, CCr<50: OR=0.91, CI: 
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0.70-1.17) as shown in Table 6. After additional adjustment of diabetes 
mellitus and smoking, there was significantly low risk at CCr<50 (OR=0.54, 
CI: 0.30-0.95). However, these significances disappeared after additional 
adjustment of hypertension (OR=0.70, CI: 0.42-1.14). Indeed, eGFR was 
inversely correlated with BMI (r = -0.072, p<0.0001), and CCr was positively 
correlated with BMI (r = 0.458, p<0.0001) when the relationship between 
eGFR, CCr and BMI was analyzed in all subjects, respectively 
(Supplementary figure 1). Therefore, the discrepancy between the results of 
eGFR and CCr might be caused by the difference of the body weight in terms 
of BMI in each classified group as shown in Table 3 and 5.   
 Finally, the associations between eGFR or CCr and age were shown in 
Figure1. Although both indexes gradually decreased with aging, CCr was 
higher than eGFR at younger than 70 years old. In contrast, CCr was lower 
than eGFR at older than 70 years old and then inverse association was 
observed on the border of the 70 years old. 
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DISCUSSION 
 This study evaluated the prevalence and risk factors of AF by using 
database of annually health checkup in the general population living in the 
middle part of Japan. The multivariate logistic regression analysis showed 
that female (OR = 3.65 vs. male), age > 65 years old (OR = 2.52 vs. < 65 years 
old) were independently high risks of prevalence of AF in this study. The 
prevalence of AF was 0.92% among aged ≥20 years. AF was rare <60 years 
old in men (0.29%) or <70 years old in women (0.14%), and there was four 
times higher in men than in women in this all population (1.46% vs. 0.37%). 
Thus, AF was strongly associated with age and gender.  
 The prevalence of AF for each decade of advancing age of men and women 
found in the present study are comparable with those previously reported.16 
However, our findings that the higher prevalence rate of AF was observed in 
the men from 60 to 80 years old and the women above 80 years old compared 
with those of previous report,20 which might be relate that there was a 
difference of one decade between our study and those previous studies. In 
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our country, the prevalence of AF has been estimated to rise by the increase 
of the aging population.20  
BMI >25 was also risk factor of the prevalence of AF (OR=1.37) in this study. 
Obesity has been associated to increased risk of AF, it was associated with a 
4–5% increased risk of AF over a mean follow-up of 14 years, independently 
of hypertension, diabetes mellitus, and myocardial infarction in the 
Framingham Heart study.21 This relationship may be mediated by an 
increase in left atrial diameter, which can be attenuated by weight loss.22  
Atrial stretch enhances the vulnerability of the atrium that trigger to AF.23 
The Women’s Health study reported a linear relationship between BMI and 
AF, with a 5% increase in risk of AF for a 1-unit increase in BMI.24  
 Although our data showed that cardiac disease was complicated more 
frequently in both men and women with AF than in those without, the 
cardiac disease was simply collected by the questionnaire when there was 
more than one item: the currently treatment, only follow-up, completion of 
treatment and without treatment. Thus, the loan AF might be included in 
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the category of cardiac disease. For this reason, the rate of comorbidity with 
cardiac disease may be high in both genders in AF compared with previous 
studies. With the exception of cardiac disease, the complications of 
hypertension and diabetes mellitus were more than two times frequent in 
both men and women with AF compared with those without AF. Moreover, 
the multivariate logistic regression analysis demonstrated hypertension (OR 
= 1.14 vs. normotension) was independently high risk of prevalence of AF. It 
has also reported that hypertension is the most prevalent risk factor for 
incidence of AF25-27 and was complicated more frequently with AF.20 Of note, 
the stepwise regression analysis of the continuous variables revealed that 
SBP at the time of health examination (OR=1.07) was the independently 
associated with high risk of prevalence of AF in this study. Cardio-Sis trial 
demonstrated that new-onset atrial ﬁbrillation occurred less in the blood 
pressure tight-control (SBP<130 mm Hg) than in the usual-control group 
(SBP<140 mm Hg) for two years treatment in hypertensive patients without 
diabetes mellitus.28 Taken together, these data suggested that inadequate 
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antihypertensive treatment was unable to prevent AF.  
 Diabetes mellitus and other risk-factors were also comparable with those 
previously reported.20 Diabetes mellitus (OR = 2.38, p <0.0001) was a 
significant risk factor of AF by the simple logistic regression analysis but not 
multivariate logistic regression analysis. It might be suggested that other 
confounding variables were stronger association with prevalence of AF. 
 In generally, it has been reported that reverse epidemiology, i.e. the 
cholesterol paradox, does exist between lipid profile and AF, whereby low 
level of HDL cholesterol and LDL-cholesterol or triglyceride are positively 
related to increasing AF.29,30 The mechanism of this relationship was 
speculated by Suzuki.31 Although the hyperlipidemia was collected by simply 
questionnaire, there was no association between lipid profile such as HDL, 
LDL cholesterols and triglyceride levels at the time of health examination 
and the prevalence of AF in this study (data was not shown).  
Although the glomerular filtration rate (GFR) was estimated by creatinine 
clearance in the practical medicine, both indexes were strictly different.  
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Cockcroft-Gault formula (CCr) by using age, body weight, serum creatinine 
and gender was proposed.16 Even in current, United States Food and Drug 
Administration recommends that drug dosage is adjusted by CCr in patients 
with impaired renal function, and do not approve to substitute estimated 
GFR (eGFR) in place of CCr for renal dosing of drugs.8 Previously, serum 
creatinine was measured by the Jaffe method, which was higher than that 
by the current enzymatic assay, which makes to be slightly overestimation 
especially in eGFR>60ml/min/1.73m2.32 On the other hand, Lindeman et al.33 
reported that the mean decrease in creatinine clearance with aging was 0.75 
ml/min/year, which smaller than the predicted value of CCr (1.0 
ml/min/year). Thus, CCr tend to underestimate creatinine clearance of the 
elderly subjects. Actually, our data demonstrated that CCr was lower than 
eGFR above 70 years old and then, the inverse relationship was observed 
below 70 years old. Moreover, the value of CCr will vary greatly depending 
on body weight.16 In the present study, the body weight was gradually 
decreased with lower classified category of CCr (Table 5). In contrast, the 
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overall analysis revealed that the high BMI which positively correlated with 
the CCr was one of the most important risks of the prevalence of AF in our 
study. Therefore, the lower category of CCr group was associated with the 
lower body weight and higher rate of woman, which might be low prevalence 
of AF. 
Of note, CCr is an estimation of the creatinine clearance, but not of the GFR, 
and was suboptimal performance for GFR estimation, especially in advanced 
kidney disease which included tubular creatinine secretion.34,35 Therefore, 
Levey et al.36 published new formula based on patients who had a 
GFR<60ml/min/1.73m2 from the Modification of Diet in Renal Disease 
(MDRD) study. The formula was found to be superior to the Cockcroft Gault 
formula for estimating GFR. However, the MDRD study was developed in 
mostly whites and African Americans. Matsuo et al.37 reported that eGFR 
obtained using the isotope-dilution mass spectrometry–traceable 4-variable 
MDRD Study equation was significantly higher than measured GFR by 
inulin clearance in Japanese patients and calculated a correction coefficient 
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of 0.808 for the MDRD Study equation and developed a new Japanese 
equation for GFR estimation.  
Although the best overall index of renal function is the GFR,38 measuring 
GFR was cumbersome and taking a lot of time. eGFR is currently used by 
most clinical laboratories, that is reliable and convenient index for the 
diagnosis and evaluation of chronic kidney disease. The chronic kidney 
disease was staged by levels of eGFR according to the KDIGO clinical 
practice guideline of chronic kidney disease.15 The eGFR was calculated by 
the adjustment of the standard body surface area (1.73m2), and the value 
was apart from real value when the body weight or/and height deviated from 
standard value. However, there were almost equal in the mean body weight 
and height in the three classified category groups of eGFR in this study 
(Table 3). Thus, the odds ratio of the risk of having AF was significantly high 
risks at the lowest category of eGFR (≦59) compared with the highest 
category of eGFR (≧90) after adjustment of the age, gender, diabetes 
mellitus and smoking on the multivariate logistic regression analysis 
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(OR=2.10, CI: 1.21-3.86, Table 4). Recently, Ohyama et al.39 also reported 
that eGFR≦59 ml/min/m2 was strongly associated with prevalence of AF 
after adjustment of the age, gender, diabetes mellitus, smoking as well as 
hypertension and cardiac disease on the multivariate logistic regression 
analysis in the community-based population in Gunmma prefecture. The 
discrepancy of these results between our and above cited studies may be 
explained by the differences of age (56.5 vs. 53.2 years old), gender (male: 
48.2% vs. 62.0%) and/or number of subjects (20,091 vs. 85,414), which have 
an effect on the prevalence of AF. Another possible reason is the prevalence 
of AF in high GFR group has too small (6/3,148 subjects, 0.19%) that is 
biased in the latter study compared with our study (44/15,491 subjects, 
0.28%). In our study, eGFR but not CCr was significantly associated with 
prevalence of AF, which has been suggested in our country.40,41 However, this 
significant association was disappeared after adjustment of the confounding 
variables such as cardiac disease and hypertension in the multivariate 
regression analysis. Thus, it was considered that these variables were closely 
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connected with eGFR 
Atrial fibrillation and flutter were defined the AF in this study, because only 
13 patients (1.3%) were diagnosed with atrial flutter by the automated 
computerized analysis. Moreover, atrial flutter and fibrillation sometimes 
coexist as they are the electrical consequence of the same arrhythmogenic 
substrate. The frequency of the coexistence of the two arrhythmias is not 
easily predictable because both arrhythmias are often silent. Randomized 
controlled trial of atrial fibrillation also included patients with atrial 
flutter.42,43 
 
Limitations 
  Various limitations apply to the present study. Firstly, this was 
cross-sectional observation study. Thus, the mechanism between prevalence 
of AF and risk factors for AF was not known. Secondary, prevalence of AF 
was only defined by standard 12-lead electrocardiographic recording at one 
time. Almost of all paroxysmal AF was excluded in this study. Thirdly, 
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medical histories of risk factors for AF were only collected by the 
questionnaire at the annular healthy check-up, the actual medical history 
was difficult to correct in some cases, which might be limited and would have 
caused a bias in the results. Fourthly, some patients with medication were 
included in this cohort, may influence prevalence of AF. Lastly, the eGFR 
equation by the MDRD study was developed in mainly in CKD patients and 
the accuracy was still moderate particularly in the GFR>60ml/min/1.73m2,36 
then eGFR is calculated to be lower value when the MDRD equation applied 
to healthy subjects. To improve this weak point, CKD-EPI formula using the 
different estimating equation by the value of serum creatinine has been 
devised in the United States.44 However, the estimated error of the eGRF 
calculated by modified CKD-EPI formula was greater than that calculated 
by modified MDRD in Japanese subjects with GFR<60ml/min/1.73m2.45 
Thus, the eGFR calculated by CKD-EPI formula is not suitable for the 
Japanese subjects at present time.  
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Conclusion 
 The prevalence of atrial fibrillation actually rises with increasing aging 
population in living in the middle part of Japan. Cardiac disease, gender, 
aging, hyperlipidemia, obesity, hypertension especially in systolic blood 
pressure and renal dysfunction were strong risk factors for prevalence of AF. 
The evaluation of renal dysfunction as a morbidity risk of atrial fibrillation 
was suggested that eGFR should be used instead of CCr (Cockcroft-Gault 
formula) in general population in this area.  
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FIGURE LEGENDS 
Figure 1.  Correlation between CCr, eGFR and age. 
eGFR: estimated glomerular filtration rate, CCr: creatinine clearance 
(Cockcroft-Gault formula), min: minutes, 
Red color was correlation line and 95% confidential interval of CCr.  
Blue color was correlation line and 95% confidential interval of eGFR.  
 
Supplementary Figure 1.  Correlation between eGFR, CCr and bpdy mass 
index (BMI) 
eGFR: estimated glomerular filtration rate, CCr: creatinine clearance 
(Cockcroft-Gault formula), min: minutes, 
 
 
